Aimfinity Investment is a SPAC — a blank check shell company with no operations, revenue, or employees beyond two part-time executives. Aimfinity raised $80.5M in an April 2022 IPO, placing proceeds into a trust account to fund an acquisition. Aimfinity has identified its target: Docter, a company developing non-invasive blood sugar monitoring technology, health-tracking smartwatches, and a cloud-based health monitoring platform. Shareholders approved the proposed merger in March 2025. Under the deal terms, Docter shareholders receive 6M shares in a newly formed public holding company at a $60M implied equity value, with up to 2.5M additional earnout shares tied to device sales milestones in FY2025 and FY2026. The deal has faced heavy shareholder redemptions — roughly 7M of the original 8.05M public shares have been redeemed across three extension votes, leaving minimal trust funds remaining. A backstop investor has agreed to purchase shares at $10.00 each to ensure the deal meets minimum net tangible asset requirements at closing. The deal deadline is April 28, 2025, with possible extensions to October 2025. The sponsor, controlled by Chairman and CEO I-Fa Chang, holds approximately 1.69M founder shares issued at minimal cost, which only have value if the merger closes. Chang has also personally funded over $2.6M in working capital loans and extension deposits, most of which will convert to equity at closing.